Skip to content


    DEA Class; Rx

    Common Brand Names; Otezla

    • DMARDs, PDE4 Inhibitors

    Oral phosphodiesterase-4 inhibitor (PDE4) and a targeted synthetic DMARD
    Used in adults for the treatment of active psoriatic arthritis, oral ulcers associated with Behcet’s Disease, and plaque psoriasis in candidates for systemic or phototherapy
    Patients with severe diarrhea, nausea, and vomiting may need dose reduction or drug discontinuation

    Indicated for the treatment of active psoriatic arthritis.

    For the treatment of plaque psoriasis in patients who are candidates for phototherapy or systemic therapy.
    For the treatment of oral ulcers (aphthous ulcer, canker sores) associated with Behcet’s syndrome.

    Hypersensitivity to apremilast or to any of the excipients in the formulation

    • Diarrhea (7.7-17%)
    • Nausea (7.4-17%)
    • Diarrhea (41.3%)
    • Nausea (19.2%)
    • Headache (14.4%)
    • Upper respiratory tract infection (11.5%)
    • Upper abdominal pain (8.7%)
    • Vomiting (8.7%)
    • Back pain (7.7%)
    • Viral upper respiratory tract infection (6.7%)
    • Arthralgia (5.8%)

    Hypersensitivity reactions, including angioedema and anaphylaxis, reported; with known hypersensitivity to apremilast; if signs or symptoms of serious hypersensitivity reactions develop during treatment, discontinue and institute appropriate therapy

    Associated with an increase in adverse reactions of depression; before using, evaluate patient for history of depression and/or suicidal thoughts or behavior

    Weight decrease of 5-10% of body weight reported in 10-12% of patients

    Because patients 65 years of age or older may be at a higher risk of complications such as volume depletion or hypotension from severe diarrhea, nausea, or vomiting, monitor geriatric patients closely for such complications

    Available pharmacovigilance data use in pregnant women have not established a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes, but data are extremely limited

    There are no data on the presence of apremilast in human milk, the effects on the breastfed infant, or the effects on milk production


    60 mg/day PO.


    60 mg/day PO.


    Safety and efficacy have not been established.


    Safety and efficacy have not been established.


    Safety and efficacy have not been established.


    Safety and efficacy have not been established.



    • 10mg
    • 20mg
    • 30mg